関連する実験動画
Updated: May 6, 2026
13:08
Creation and Maintenance of a Living Biobank - How We Do It
Published on: April 10, 2021
7.6K
トランスレーション研究と精密医療のための患者由来オルガノイドバイオバンク:課題と将来の展望
Floriana Jessica Di Paola1, Giulia Calafato1, Pier Paolo Piccaluga1
1Biobank of Research, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Journal of personalized medicine
|August 27, 2025
まとめ
患者からのオーガノイド (PDO) は 癌研究と精密医療に革命をもたらしています 生きたPDOバイオバンクは 薬のスクリーニングとバイオマーカーの発見に不可欠なプラットフォームを提供し パーソナライズされたがんケアを進めている.
科学分野:
- 生物医学工学
- 腫瘍学
- 翻訳医学
背景:
- 患者に由来するオーガノイド (PDO) は親の腫瘍の特徴を密接に模倣する.
- 生きた PDO バイオバンクは 薬剤のスクリーニングとバイオマーカーの発見に不可欠です
- PDOは,がん研究と精密医療の重要な進歩を表しています.
研究 の 目的:
- 腫瘍と健全な組織特有のPDOバイオバンクの分類とグローバルな分布を見直す.
- PDOバイオバンクの翻訳的な応用を探求する.
- PDOバイオバンクを臨床実践に統合するための課題と将来の方向性について議論する.
主な方法:
- PDOのバイオバンクに関する既存の文献のレビュー
- PDOバイオバンク分類とグローバル分布の分析
- オーガノイド培養システムと培養媒体の進歩に関する議論
主要な成果:
- PDOのバイオバンクは,様々な研究アプリケーションをサポートするために,世界中でますます確立されています.
- 標準化とアクセシビリティの取り組みが拡大しています.
- 培養システムにおける最近の進歩は,長期的な生存能力を向上させ,腫瘍の微小環境を模倣することを目的としています.
結論:
- PDOバイオバンクは パーソナライズド医療とがん研究にとって不可欠なツールです
- 培養と維持の技術的な課題を克服することは,臨床統合の鍵です.
- 将来の取り組みは,標準化,アクセシビリティ,臨床翻訳に焦点を当てるべきです.
関連する概念動画
01:29Issues And Trends In Healthcare Delivery System
6.5K
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
6.5K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
631
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
631
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
252
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
252
01:13Bioequivalence studies: Biowaivers
433
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
433
01:29Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129